Study Stopped
Compound will not be studied for indication
Compound will not be studied for indication
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
Sponsor study identifier
interventional
0
1 country
3
Study Start
March 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This study will be conducted as a multi-center, open label study in the US. There will be 40 patient to receive the active investigational product.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 18, 2019
Actual (reported)May 6, 2019
Actual (reported)March 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Cognition Improvement by Dementia Severity Rating Scale (DSRS) - Primary Outcome
To determine the safety and efficacy of repeated oral doses of ENT-01 in improving cognition in patients with Parkinson's disease dementia, measured by the Dementia Severity Rating Scale (DSRS). The DSRS Test is used to track changes in cognitive status over time. Its five subscales provide additional information on specific abilities: Attention, Initiation/Perseveration, Construction, Conceptualization, and Memory. The score ranges from 0 to 54, with 0-18 being mild, 19-36 being moderate and 37-54 being severe. Improvements would be indicated by lower scores from baseline to end of fixed dose period.
10 weeks
Change from Baseline in Montreal Cognitive Assessment (MOCA) - Secondary Outcomes
10 weeks
Change from Baseline to the End of the Fixed Dose Period in Symptoms Adapted for Parkinson's Disease (SAPS-PD) - Secondary Outcomes
10 weeks
Change from Baseline to the End of the Fixed Dose Period in Neuropsychiatric Inventory (NPI) and Caregiver Distress (NPI-D) - Secondary Outcomes
10 weeks
Change from Baseline to the End of the Fixed Dose Period in Parkinson's Disease Questionnaire-39 (PDQ-39) - Secondary Outcomes
10 weeks
To compare the effect of ENT-01 on motor and non-motor symptoms of Parkinson's disease including Movement Disorder Society - Unified Parkinsons' Disease Rating Scale (MDS-UPDRS).
10 weeks
To compare the effect of ENT-01 on non-motor symptoms of Parkinson's disease for skin-temperature determined Circadian rhythm and weight.
10 weeks
To compare the effect of ENT-01 on non-motor symptoms of Parkinson's disease for weight.
10 weeks
ENT-01 tablet will be taken once daily by mouth.
ENT-01 will be administered in tablet form, once daily. Other Names: ENT-01
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Neuro Pain Medical Center
Fresno, California, 93710, United States
Evolution Research Group - Neuroscience Research Institution
Toms River, New Jersey, 08755, United States
Elias Research - Neurology Diagnostics Research
Dayton, Ohio, 45459, United States
Michael Zasloff, MD, Ph.D
Enterin Inc.
Denise Barbut, MD, FRCP
Enterin Inc.
0 participants (actual enrollment reported by the registry).
First Submitted
April 18, 2019
First Posted
May 6, 2019
Study Start
March 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
Contact the study team to confirm eligibility.
Primary Completion
June 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 15, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 1, 2024
Record last verified: 2024-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: